Sr Associate Scientist I or II, Medicinal Chemistry at Axsome Therapeutics Inc

San Diego, California, United States

Apply Now

$84,000 – $120,000Compensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

BS in Chemistry with 5+ years experience (pharma/biotech) or MS in Chemistry with 3+ years experience (pharma/biotech)
Proven skills in multi-step organic synthesis, reaction optimization, SAR analysis, and scientific presentation
Ability to thrive in a fast-paced, highly collaborative research environment
Availability to work onsite in San Diego

Responsibilities

Design, synthesize, purify, and characterize chemical compounds (10 mg–5 g scale) using modern analytical techniques such as LCMS, HPLC, and NMR, employing both individual and automated parallel synthesis approaches
Identify and optimize reaction conditions using screening kits and other streamlined methodologies
Collaborate with the high-throughput experimentation team to ensure the successful execution of parallel chemistry experiments
Analyze biological and ADME-PK data using cheminformatics tools and contribute to data-driven discussions and strategic planning
Partner with computational chemists to leverage machine learning insights for efficient execution of the design–make–test cycle and platform development
Present results to project teams and senior leadership, clearly communicating data, implications, and recommendations

Skills

Organic Synthesis

Medicinal Chemistry

LCMS

HPLC

NMR

Parallel Synthesis

Reaction Optimization

SAR Analysis

Cheminformatics

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free